45
Participants
Start Date
October 11, 2017
Primary Completion Date
December 10, 2018
Study Completion Date
November 19, 2020
zilucoplan (RA101495)
Daily subcutaneous (SC) injection
Placebo
Daily subcutaneous (SC) injection
Hospital for Special Surgery, New York
Mount Sinai Hospital, New York
University of Buffalo, Buffalo
Allegheny Neurological Associates, Pittsburgh
George Washington University, Washington D.C.
University of Maryland, Baltimore
University of North Carolina at Chapel Hill, Chapel Hill
University of Florida, Jacksonville
University of South Florida, Tampa
Diagnostic and Medical Clinic - Mobile, Mobile
Wesley Neurology Clinic, Cordova
Ohio State University, Columbus
Wayne State University, Detroit
Michigan State University, East Lansing
Center for Neurological Disorders, Milwaukee
Rush University Medical Center, Chicago
University of Kansas Medical Center, Kansas City
University of Texas Southwestern, Dallas
University of Utah, Salt Lake City
UCLA Medical Center, Los Angeles
The Research Center of Southern California, Carlsbad
University of California Irvine Health ALS and Neuromuscular Center, Orange
Yale University, New Haven
Massachusetts General Hospital, Boston
Lahey Hospital and Medical Center, Burlington
University of Vermont, Burlington
University of Alberta Hospital, Edmonton
London Health Sciences Centre University Hospital, London
Toronto General Hospital, Toronto
Montreal Neurological Institute and Hospital, Montreal
Lead Sponsor
Ra Pharmaceuticals
INDUSTRY